Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
canocapavir + nucleos(t)ide analog
- Development stage
- Discontinued
- Lead developer
- Janssen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Canocapavir (JNJ-6379) is a small molecule capsid assembly modulator (CAM) that was under development by Janssen for the treatment of chronic hepatitis B virus (HBV) infection. It functions by binding to the HBV core protein, inducing the assembly of aberrant or empty capsids, thereby preventing the encapsidation of pregenomic RNA and subsequent viral replication. In clinical development, canocapavir was frequently studied in combination with nucleos(t)ide analogs (NUCs), such as tenofovir or entecavir, which act as reverse transcriptase inhibitors to suppress viral DNA synthesis. This combination approach was intended to target multiple stages of the HBV lifecycle to improve functional cure rates. Janssen discontinued the development of canocapavir in late 2022 as part of a strategic reprioritization of its HBV portfolio.
- Other names
- JNJ-6379 + NUCJNJ-6379 + nucleoside analog
02
Targets
HBV Pol (Hepatitis B virus polymerase)HBc (Hepatitis B virus core protein)
Beyond the preview
Go deeper on canocapavir + nucleos(t)ide analog.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on canocapavir + nucleos(t)ide analog.